Luxéol Chute de cheveux réactionnelle, gélule
Food supplement declared in France, decision dated 6 January 2025
Luxéol Chute de cheveux réactionnelle, gélule, from LUXEOL, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Adiantum capillus-veneris 150 mg per day, Equisetum arvense 30 mg per day, Eschscholzia californica 30 mg per day, Biotin (vitamin B8), Selenium. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- Luxéol
- Food business operator placing the product on the market
- LUXEOL
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 gélule par jour
- Directions for use
- prendre 1 gélule par jour à avaler avec un grand verre d'eau
- Intended populations
- Men, Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women, Heart problems, Taking diabetes medication
- Objectives stated by the manufacturer (these are not authorised claims)
- Hair and nails
Declaration 3753, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Adiantum capillus-veneris L. | Parties aériennes | Extrait sec aqueux | 150 mg |
| Equisetum arvense L. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 30 mg |
| Eschscholzia californica Cham. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 30 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Méthionine | not declared |
| L-cystine | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| sodium selenite | Selenium | 255 µg | 50 µg |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| zinc citrate | Zinc | 25 mg | 15 mg |
Additives
E470b, E553b, E341, E464
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Réservé à l’adulte. Déconseillé aux femmes enceintes ou allaitantes ainsi que chez les personnes sous antidiabétiques. Déconseillé en cas d'insuffisance cardiaque ou rénale oedémateuse. Les compléments alimentaires doivent être utilisés dans le cadre d'un mode de vie sain et ne pas être utilisés comme substituts d'un régime alimentaire varié et équilibré. Tenir hors de la portée des jeunes enfants. Ne pas dépasser la dose journalière recommandée. À conserver au frais, au sec et à l'abri de la lumière.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Eschscholzia californica Cham.
Read the warning, when it applies and the studies cited
CALIFORNIA POPPY - ESCHSCHOLZIA CALIFORNICA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
When using this product avoid taking with alcohol or products that cause drowsiness and/or with analgesic properties (Brinker 2010; Mills and Bone 2005; Hoffmann 2003).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2015; Berardi et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- EMA 2015: European Medicines Agency. European Union herbal monograph on Eschscholzia californica Cham., herba London. (UK): Committee on Herbal Medicinal Products (HMPC); 2015. [Accessed 2024 March 1]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf.
Contraindications
Do not use if you are pregnant (Brinker 2010; Blumenthal et al. 2000).
Sources cited by Health Canada (2)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Luxéol Chute de cheveux réactionnelle, gélule Luxéol, declared in 2021 : same declared composition
Brand : Luxéol
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Luxéol Chute de cheveux réactionnelle, gélule: composition and regulation”, https://compoatlas.com/en/supplements/products/3753-luxeol-chute-de-cheveux-reactionnelle-gelule, updated 15 November 2026.